Clinical trials
Terminated Phase 2 Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
206 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 4 |
| 2003 | 8 |
| 2004 | 2 |
| 2005 | 16 |
| 2006 | 19 |
| 2007 | 13 |
| 2008 | 14 |
| 2009 | 18 |
| 2010 | 6 |
| 2011 | 7 |
| 2012 | 13 |
| 2013 | 7 |
| 2014 | 10 |
| 2015 | 7 |
| 2016 | 8 |
| 2017 | 1 |
| 2018 | 9 |
| 2019 | 6 |
| 2020 | 8 |
| 2021 | 10 |
| 2022 | 7 |
| 2023 | 6 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 206 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 7 |
| GlaxoSmithKline | 6 |
| M.D. Anderson Cancer Center | 5 |
| University of Utah | 5 |
| AstraZeneca | 4 |
| AbbVie | 3 |
| Centre Oscar Lambret | 3 |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 3 |
| Mayo Clinic | 3 |
| Novartis Pharmaceuticals | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neoplasms | 206 |
| Neoplasm Metastasis | 39 |
| Breast Neoplasms | 14 |
| Colorectal Neoplasms | 14 |
| Recurrence | 14 |
| Carcinoma, Renal Cell | 12 |
| Lymphoma, Non-Hodgkin | 12 |
| Ovarian Neoplasms | 11 |
| Prostatic Neoplasms | 11 |
| Lymphoma | 10 |
Trials
Showing 1 to 25 of 206. Each trial links to its page on Pharma Observatory.
106 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.